Semaglutide and Fatty Liver in 2026: New Wegovy Data Shows Liver Fat Returning to Normal in 9 of 10 Patients

The new data comes from a pooled analysis of the STEP UP and STEP UP T2D trials, two phase 3b studies of semaglutide for weight management announced on October 1, 2026. Across 1,919 adults, researchers looked at a subgroup of 55 participants whose liver fat was measured with MRI-PDFF — the gold-standard imaging method for quantifying fat in the liver.

The headline results after 72 weeks of treatment:

Among participants taking semaglutide, average liver fat fell from 8.8% to 3.1% — a reduction of nearly two-thirds. Of the 26 participants who started with liver fat above 5% (the threshold generally considered abnormal), 23 of them — 88.5% — dropped below that threshold by week 72. In other words, roughly 9 out of 10 people with excess liver fat saw it return to the normal range.

The weight loss results from the parent trials were equally notable: in STEP UP, participants lost an average of 18.7% of their body weight on semaglutide 7.2 mg and 15.6% on the approved 2.4 mg dose, versus 3.9% on placebo.

Dr. Eric Lawitz of the Texas Liver Institute, the analysis's lead author, said the findings suggest semaglutide "may help address liver disease early – before it becomes a serious health problem."

Excess fat in the liver — now called metabolic dysfunction-associated steatotic liver disease, or MASLD (formerly "fatty liver disease") — is one of the most common chronic liver conditions, and it travels closely with the same metabolic issues that drive weight gain: insulin resistance, elevated blood sugar, and high triglycerides.

The problem is that MASLD is usually silent. Most people have no symptoms for years while fat quietly accumulates. In a subset of patients, that fat triggers inflammation (a more serious stage called MASH) and scarring that can progress toward cirrhosis. In the new analysis, more than 94% of participants were classified as high risk for fatty liver on a standard screening index — a reminder of how common this is in people carrying extra weight, even when nothing feels wrong.

That is why this data matters for patients, not just researchers: it suggests the same medication many people take to lose weight may also be clearing fat out of the liver at the same time, potentially interrupting that silent progression early.

This is encouraging data, but it deserves an honest reading.

First, it is a post hoc, exploratory analysis — liver fat was not a primary goal of these trials, and the imaging subgroup was small (55 people, with only 26 starting above the 5% threshold). Second, no placebo comparison was reported for the liver fat outcomes themselves, so some of the improvement can't be cleanly separated from chance or lifestyle changes. Third, the trials were funded by Novo Nordisk. And finally, the pooled results include a 7.2 mg dose of semaglutide that is still investigational — the approved Wegovy dose for weight management remains 2.4 mg.

None of that makes the result unimportant. It fits a consistent pattern across semaglutide research, and MRI-PDFF is a rigorous way to measure liver fat. But a 26-person subgroup is a signal, not a guarantee of what any individual patient will experience.

This analysis did not come out of nowhere. According to Novo Nordisk's announcement, semaglutide 2.4 mg is already approved to treat MASH in several markets — including the United States — in patients with the more advanced, inflammatory stage of the disease. The ongoing phase 3 ESSENCE trial is studying semaglutide in MASH with moderate to advanced fibrosis, with longer-term results expected in 2029.

The new EASD data extends the picture earlier in the disease: it suggests benefit not just for people who already have serious liver inflammation, but for the much larger group of patients with obesity whose livers are quietly accumulating fat.

For patients comparing options, it is worth noting this is a class-wide area of interest — liver benefits are being studied across GLP-1 and dual-agonist medications, including tirzepatide. If you want a deeper look at how these medications compare on weight loss itself, see our tirzepatide dosage guide or talk through the options with a provider.

Semaglutide's side effect profile in these trials was consistent with what is already known. Gastrointestinal effects — nausea, constipation, diarrhea, vomiting — were the most common, affecting 61% of participants on the 2.4 mg dose, and they are typically mild to moderate and most noticeable during dose increases. Many patients manage them with slower titration, dietary adjustments, or anti-nausea support.

GLP-1s are not right for everyone. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, a history of pancreatitis, or during pregnancy. If you have known liver disease, significant alcohol use, or abnormal liver enzymes on past bloodwork, those details belong in your intake conversation — they shape both whether a GLP-1 is appropriate and what monitoring makes sense. Treatment decisions should always be made with a licensed provider who has reviewed your full health history.

If you have been thinking about GLP-1 treatment — for weight, metabolic health, or both — the first step is a proper medical evaluation, not a guess. JoeyMed's licensed providers review your health history, discuss whether semaglutide or tirzepatide fits your situation, and build a plan that includes dose titration and side effect management.

You can start an online visit today at JoeyMed Weight Loss — no insurance required, with transparent pricing and ongoing provider support. Your liver may end up thanking you for a decision you made about your weight.

This article is for educational purposes and is not medical advice. GLP-1 medications are prescription treatments; whether they are appropriate for you is a decision to make with a licensed healthcare provider.